LXRX logo

LXRX

Lexicon Pharmaceuticals Inc.

$1.10
-$0.05(-4.35%)
41
Overall
--
Value
54
Tech
28
Quality
Market Cap
$414.27M
Volume
1.49M
52W Range
$0.28 - $2.17
Target Price
$2.75
Order:

Income Statement

MetricTrendChart
2015
Dec
2016
Dec
2017
Dec
2018
Dec
2019
Dec
2020
Dec
2021
Dec
2022
Dec
2023
Dec
2024
Dec
REVENUE
Total Revenue
$130.0M$83.3M$91.5M$62.9M$321.6M$23.4M$298.0K$139.0K$1.1M$6.0M
Total Revenue
$130.0M$83.3M$91.5M$62.9M$322.1M$24.0M$298.0K$139.0K$1.2M$31.1M
COST OF GOODS SOLD
Cost of Revenue
----$1.9M$2.5M$3.2M$1.9M----$85.0K$616.0K
GROSS PROFIT
Gross Profit
$130.0M$83.3M$89.6M$60.4M$318.8M$22.1M$298.0K$139.0K$1.1M$30.5M
OPERATING EXPENSES
Operating Expenses
$-128.5M$220.5M$220.4M$164.0M$180.6M$204.4M$87.4M$100.9M$172.9M$243.2M
Research & Development
$95.2M$178.2M$152.2M$100.2M$91.9M$153.6M$55.0M$52.8M$58.9M$84.5M
Research Expense
$95.2M$178.2M$152.2M$100.2M$91.9M$153.6M$55.0M$52.8M$58.9M$84.5M
Selling, General & Administrative
$23.8M$43.0M$66.1M$63.8M$56.8M$47.2M$32.3M$48.1M$114.0M$143.1M
General & Administrative Expenses
$23.8M$43.0M$66.1M$63.8M$56.8M$47.2M$32.3M$48.1M$114.0M$143.1M
Salaries & Wages
----------$-132.6M----$14.3M$13.5M
Amortization
----$-1.5M$-1.8M$1.8M----$44.5M$44.5M$44.5M
Other Operating Expenses
$5.9M$-703.0K$2.1M--------$2.8M$13.1M$15.6M
OPERATING INCOME
Operating income
$5.1M$-137.2M$-130.8M$-103.6M$141.4M$-47.8M$-87.1M$-100.8M$-171.8M$-197.1M
EBITDA
$3.3M$-132.3M$-124.7M$-96.1M$148.4M$-41.1M$-86.7M$-98.7M$-166.4M$-198.0M
NON-OPERATING ITEMS
Interest Expense (Non-Operating)
$6.7M$6.6M$7.0M$20.8M$20.7M$14.5M$802.0K$2.8M$13.1M--
Interest Income Operating
$1.3M------------------
Net Non-Operating Interest Income/Expense
$-6.7M$-6.6M$-7.0M$-20.8M$-20.7M$-14.5M$-802.0K$1.2M$5.4M--
Gain on Sale of Securities
----$7.0K--------------
Other Income/Expense
$-572.0K$-2.3M$-2.0M$-3.5M$-3.9M$-2.7M$-432.0K$-1.7M$-7.8M$-37.4M
Other Special Charges
$572.0K$2.3M$2.0M$3.5M$3.9M$4.3M$432.0K$1.7M$7.8M$37.4M
SPECIAL ITEMS
Restructring And Mn A Income
----------$5.5M--------
Special Income Charges
$-3.6M--$178.0K$355.0K$-28.6M$-5.5M--------
Impairment of Capital Assets
$3.6M------$28.6M----------
PRE-TAX INCOME
EBIT
$2.0M$-134.9M$-128.7M$-99.8M$144.8M$-44.0M$-87.0M$-99.2M$-168.7M$-200.4M
Pre-Tax Income
$-4.7M$-141.4M$-135.7M$-120.5M$124.1M$-58.6M$-87.8M$-101.9M$-177.1M$-200.4M
INCOME TAX
Tax Provision
----$-12.7M$-115.0K$-6.0M$-269.0K----$-4.7M--
NET INCOME
Net Income
$-4.7M$-141.4M$-123.0M$-120.5M$130.1M$-58.6M$-87.8M$-101.9M$-177.1M$-200.4M
Net Income (Continuing Operations)
$-4.7M$-141.4M$-123.0M$-120.5M$130.1M$-58.6M$-87.8M$-101.9M$-177.1M$-200.4M
Net Income (Discontinued Operations)
$-4.7M$-141.4M$-123.0M$-120.5M$130.1M$-58.6M$-87.8M$-101.9M$-177.1M$-200.4M
Net Income (Common Stockholders)
$-4.7M$-141.4M$-123.0M$-120.5M$130.1M$-58.6M$-87.8M$-101.9M$-177.1M$-200.4M
Normalized Income
------------$-69.3M----$-200.0M
TOTALS
Total Expenses
$-128.5M$220.5M$222.3M$166.5M$183.9M$206.3M$87.4M$100.9M$173.0M$243.8M
SHARE & EPS DATA
Average Shares Outstanding
$103.6M$103.9M$105.2M$105.8M$106.2M$110.8M$145.7M$165.7M$221.1M$320.0M
Average Shares Outstanding (Diluted)
$115.8M$103.9M$105.2M$105.8M$116.7M$110.8M$145.7M$165.7M$221.1M$320.0M
Shares Outstanding
$103.8M$104.3M$105.6M$106.3M$107.0M$144.4M$363.4M$188.7M$246.2M$361.5M
Basic EPS
$0.84$-1.36$-1.17$-1.14$1.23$-0.53$-0.60$-0.62$-0.80$-0.63
Basic EPS (Continuing Operations)
--$-1.36$-1.17$-1.14$1.23$-0.53$-0.60$-0.62$-0.80$-0.63
Diluted EPS
$-0.05$-1.36$-1.17$-1.14$1.16$-0.53$-0.60$-0.62$-0.80$-0.63
Diluted EPS (Continuing Operations)
------$-1.14$1.16$-0.53$-0.60--$-0.80$-0.63
OTHER METRICS
Gain On Sale Of P P E
------------------$1.6M
Net Income Discontinuous Operations
------$-33.7M$-15.4M$-12.2M--------
Other Gain Loss From Disposition Of Discontinued Operations
------$-33.7M$-15.4M$-12.2M--------
Other Gand A
$23.8M$43.0M$66.1M$63.8M$56.8M$47.2M$32.3M$48.1M$114.0M$143.1M
Other Impairment Of Capital Assets
--------$28.6M$1.6M--------
Rent And Landing Fees
$23.8M$-500.0K$-600.0K------$-800.0K$-1.1M$-800.0K$-1.4M
Othspecchg
----$-178.0K$-355.0K------------
Restruct
----------$5.5M--------

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2LXRX$1.10-4.3%1.49M
3
4
5
6

Get Lexicon Pharmaceuticals Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.